Insights

Global scale WuXi Biologics operates as a leading global open-access biologics platform with end-to-end capabilities, signaling strong potential for multi-region manufacturing partnerships and supply-chain collaborations across the US, China, Ireland, Germany, and Singapore.

Sustainability leadership Recent awards for green and digital transformation position WuXi Biologics as a preferred partner for ESG-conscious biopharma companies seeking sustainable manufacturing, energy efficiency, and digital process intensification vendors.

Financial momentum H1 2026 results show solid revenue growth and expanding profitability, indicating healthy demand for their biomanufacturing and CRO/CDMO services, which can be leveraged to pursue larger, longer-term collaborations.

Technology stack Adoption of advanced analytics and digital tools (Power BI, SAS, Tableau, Kubernetes) suggests readiness to integrate client data platforms, optimize process analytics, and offer data-driven manufacturing and development services.

Industry positioning Strong market visibility as a one-stop CRDMO with a comprehensive platform creates opportunities to target biotech startups and mid-size biopharma firms seeking rapid scale-up, full development pathways, and a global supply chain.

Similar companies to WuXi Biologics

WuXi Biologics Tech Stack

WuXi Biologics uses 8 technology products and services including Power BI, SAS, Tableau, and more. Explore WuXi Biologics's tech stack below.

Media & News

WuXi Biologics's Email Address Formats

WuXi Biologics uses at least 4 email formats:
WuXi Biologics Email FormatsExamplePercentage
First_Last@wuxibiologics.comJohn_Doe@wuxibiologics.com
56%
First.Last@wuxibiologics.comJohn.Doe@wuxibiologics.com
33%
FirstLast@wuxibiologics.comJohnDoe@wuxibiologics.com
8%
First@wuxibiologics.comJohn@wuxibiologics.com
3%

Frequently Asked Questions

What is WuXi Biologics's official website and social media links?

Minus sign iconPlus sign icon
WuXi Biologics's official website is wuxibiologics.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does WuXi Biologics generate?

Minus sign iconPlus sign icon
As of October 2026, WuXi Biologics's annual revenue is estimated to be $1B - $10B.

What is WuXi Biologics's SIC code and NAICS code?

Minus sign iconPlus sign icon
WuXi Biologics's SIC code is 2835 - In Vitro and In Vivo Diagnostic Substances and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does WuXi Biologics have currently?

Minus sign iconPlus sign icon
As of October 2026, WuXi Biologics has approximately 3.1K employees across 6 continents, including Asia, Europe and North America. Key team members include Ceo: C. Z. C., Chief Executive Officer: G. C. and Chief Quality Officer: J. X. Explore WuXi Biologics's employee directory with LeadIQ.

What industry does WuXi Biologics belong to?

Minus sign iconPlus sign icon
WuXi Biologics operates in the Pharmaceutical Manufacturing industry.

What technology does WuXi Biologics use?

Minus sign iconPlus sign icon
WuXi Biologics's tech stack includes Power BI, SAS, Tableau, Kubernetes, IBM SPSS, Procore, Smartsheet and Atlassian Confluence.

What is WuXi Biologics's email format?

Minus sign iconPlus sign icon
WuXi Biologics's email format typically follows the pattern of First_Last@wuxibiologics.com. Find more WuXi Biologics email formats with LeadIQ.

When was WuXi Biologics founded?

Minus sign iconPlus sign icon
WuXi Biologics was founded in 2010.
WuXi Biologics logo

WuXi Biologics

Pharmaceutical ManufacturingJiangsu, China1001-5000 Employees

WuXi Biologics is a Hong Kong-listed pharmaceutical manufacturing company that operates as a global open-access biologics platform providing end-to-end services to help organizations discover, develop, and manufacture biologics from concept to commercial production. The company is located at 108 Meiliang Road, Wuxi, Jiangsu 214092, China, and has an employee base of approximately 1,001 to 5,000 people. It positions itself as a platform with comprehensive capabilities and technologies across the biologics field, aiming to accelerate and transform discovery, development, and manufacturing for its global healthcare partners and patients worldwide. WuXi Biologics plans significant biopharmaceutical production capacity across the United States, China, Ireland, Germany, and Singapore, with total capacity exceeding 430,000 liters after 2024. The company operates within the pharmaceutical manufacturing industry and supports partners from concept to commercialization through an integrated service offering and a global supply chain network.

Section iconCompany Overview

SIC Code
2835 - In Vitro and In Vivo Diagnostic Substances
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2010
Employees
1001-5000

Section iconFunding & Financials

  • $1B - $10B

    WuXi Biologics's revenue is estimated to be in the range of $1B - $10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.